

Cardiovascular events in ankylosing spondylitis: a 2018 meta-analysis

In an article published in the *Annals of the Rheumatic Diseases*, Schieir *et al*¹ reported a trend of increased cardiovascular risk in patients with ankylosing spondylitis (AS). In this letter, we wish to add data to support the conclusions of that article. We performed an updated meta-analysis to investigate the risks of myocardial infarction (MI) and stroke in patients with AS and controls.

We searched PubMed to find reports of interest, published up to February 2018. We included all observational or case/control studies that reported rates of MI or stroke. We calculated the incidences of MI and stroke in a meta-analysis of proportions (inverse variance method) and expressed them in terms of 100 patient-years (pyrs) of exposure. We used the Mantel-Haenszel procedure to determine the risk ratios (RRs) of MI and stroke.

In the 18 included studies (online supplementary file), 2615 MIs were reported in patients with AS (n=51 660) over a mean follow-up period of 13 years. The incidence was 2.6% (95% CI 1.1% to 4.5%), or 0.18/100 pyrs. Twelve studies revealed the occurrence of 24 472 MIs (mean incidence: 2.0%; 95% CI 1.6% to 2.5%) in control individuals (n=1 735 909). A meta-analysis of 12 longitudinal studies showed a significant increase in the risk of MI (RR=1.44; 95% CI 1.25 to 1.67) in patients with AS compared with controls (figure 1).

In 11 longitudinal studies (n=51 990), 2183 strokes were reported in patients with AS over 14.7 years of follow-up. The incidence was 1.9% (95% CI 0.8% to 3.4%), or 0.18/100 pyrs. Seven studies reported 31 871 strokes in controls (n=1 624 844); thus, the incidence was 2.1% (95% CI 1.2% to 3.4%). A significant increase in stroke among patients with AS compared with controls was found in a meta-analysis of seven studies (RR=1.37; 95% CI 1.08 to 1.73; figure 2).

These results reinforced the conclusions of Schieir *et al*, who found that AS was associated with a significant increase in the risks of MI and stroke. The reasons for this increased cardiovascular risk are probably multifactorial. Systemic inflammation and high disease activity play pivotal roles in increased cardiovascular risk in rheumatic disease. The role of non-steroidal anti-inflammatory drugs remains an issue of debate.² Another possible explanation involves the proatherogenic profile of patients with AS who were smokers and/or hypertensive with a poor atherogenic lipid profile. Cardiovascular risk factors and systemic inflammation should be managed in AS to reduce the high cardiovascular risk. Recently, recommendations have been published for improving the cardiovascular risk profile.³ Compared with our previous meta-analysis, we found a reduction in the prevalence and risk of MI and stroke.⁴ This information is encouraging; it might be attributable to improvements in the control of cardiovascular risk in AS. However, efforts must continue because management of cardiovascular comorbidities in rheumatic disease remains insufficient.⁵




Figure 1 Myocardial infarction risk compared between patients with AS and controls. ACR, American College of Rheumatology; AS, ankylosing spondylitis; EULAR, European League Against Rheumatism; M-H, Mantel-Haenszel.




Figure 2 Stroke risk compared between patients with AS and controls. ACR, American College of Rheumatology; AS, ankylosing spondylitis; M-H, Mantel-Haenszel.

Sylvain Mathieu, Martin Soubrier

Rheumatology Department, Clermont University, Gabriel Montpied Teaching Hospital, Clermont-Ferrand, France

Correspondence to Dr Sylvain Mathieu, Rheumatology Department, Gabriel Montpied Teaching Hospital, 63003 Clermont-Ferrand, France; smathieu@chu-clermontferrand.fr

Contributors Study concept and design: SM and MS. Acquisition of data: SM. Statistical analysis and interpretation of data: SM. Drafting of the manuscript: SM. Critical revision of the manuscript for important intellectual content: SM and MS.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2019. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/annrheumdis-2018-213317>).



To cite Mathieu S, Soubrier M. *Ann Rheum Dis* 2019;**78**:e57.

Received 27 February 2018

Accepted 28 February 2018

Published Online First 9 March 2018

Ann Rheum Dis 2019;**78**:e57. doi:10.1136/annrheumdis-2018-213317

REFERENCES

- 1 Schieir O, Tosevski C, Glazier RH, *et al*. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. *Ann Rheum Dis* 2017;**76**:1396–404.
- 2 Nissen SE, Yeomans ND, Solomon DH, *et al*. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. *N Engl J Med* 2016;**375**:2519–29.
- 3 Agca R, Heslinga SC, Rollefstad S, *et al*. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. *Ann Rheum Dis* 2017;**76**:17–28.
- 4 Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. *Semin Arthritis Rheum* 2015;**44**:551–5.
- 5 Tournadre A, Pereira B, Dubost JJ, *et al*. Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up. *Clin Exp Rheumatol* 2017;**35**:296–302.